Rhabdomyosarcoma in infants younger than one year old: A report from the Italian Cooperative Group

Andrea Ferrari, Michela Casanova, Gianni Bisogno, Ilaria Zanetti, Giovanni Cecchetto, Bruno De Bernardi, Riccardo Riccardi, Paolo Tamaro, Cristina Meazza, Rita Alaggio, Vito Ninfo, Modesto Carli

Research output: Contribution to journalArticlepeer-review

Abstract

BACKGROUND. The management of rhabdomyosarcoma (RMS) in patients age <1 year is particularly problematic and requires a tailored therapeutic approach. We report on the Italian Cooperative Group's 20-year study of 50 children with RMS who were age <1 year at diagnosis. METHODS. Patients were treated using multimodality therapeutic approaches that were based on three consecutive protocols. Chemotherapy was administered to all patients, with dosages calculated according to body weight; calculated doses subsequently were reduced by 33-50%. Radiotherapy was administered to 10 patients. RESULTS. With a median follow-up of 76 months, 5-year event-free survival and overall survival rates were 42.3% and 61.7%, respectively. Local recurrence was the major reason for treatment failure. In particular, the local recurrence rate was high in patients who warranted radiotherapy but received none due to their age. Completeness of surgery and nodal involvement were the most significant prognostic factors. After a suitable reduction in dosage was made, acute toxicity was no different from what has been observed in older children. The most relevant toxic event was cardiotoxic death in a newborn (n = 1). CONCLUSIONS. The current study confirmed that the outcome for infants with RMS is less satisfactory than for older children and that infants with RMS require more careful monitoring and specific treatment guidelines. The absence of local control is the major cause of treatment failure; aggressive conservative surgery should be encouraged, but more radiotherapy may be advisable in selected cases. Intensive chemotherapy is essential; a 33% dose reduction may ensure adequate tolerance. In addition, patients age <3 months should not receive anthracyclines.

Original languageEnglish
Pages (from-to)2597-2604
Number of pages8
JournalCancer
Volume97
Issue number10
DOIs
Publication statusPublished - May 15 2003

Keywords

  • Cardiotoxicity
  • Chemotherapy
  • Infants
  • Rhabdomyosarcoma
  • Soft tissue sarcomas

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Fingerprint Dive into the research topics of 'Rhabdomyosarcoma in infants younger than one year old: A report from the Italian Cooperative Group'. Together they form a unique fingerprint.

Cite this